Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Jun 02, 2017
Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types
Data from Eight Oncotype DX Studies Across Breast, Prostate and Kidney Cancers Presented at 2017 American Society of Clinical Oncology Annual Meeting
May 30, 2017
Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types
Presentations in Breast and Prostate Cancers Highlight Ability of Tests to Answer Critical Clinical Questions and Optimize Treatment Outcomes
May 25, 2017
Genomic Health to Present at Jefferies 2017 Healthcare Conference
REDWOOD CITY, Calif. , May 25, 2017 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Jefferies 2017 Healthcare Conference in New York City on Tuesday, June 6, 2017 at 4:30 p.m. Eastern Time . To access the live and subsequently archived webcast of the
May 13, 2017
Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients
Additional Oncotype DX GPS Test Study Results Represent First-ever Prospective Validation of a Tissue-based Molecular Marker in Prostate Cancer
May 12, 2017
Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease
With New Data Presented at American Urological Association 2017 Annual Meeting, the GPS Test Becomes the Only Prostate Cancer Genomic Test Validated to Predict Both Near-term Adverse Pathology and Long-term Outcomes
May 10, 2017
Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference
REDWOOD CITY, Calif. , May 10, 2017 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas on Wednesday, May 17, 2017 at 11:20 a.m. Pacific Time .
May 09, 2017
Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress
Delivered 7 Percent Increase in Test Volume; 4 Percent Increase in Revenue
Generated 17 Percent Test Growth and 29 Percent Revenue Growth Across International Markets
Continued to Accelerate Prostate Test Adoption with 40 Percent Volume Growth and 26 Percent Revenue Growth
Improved Earnings Per Share by $0.17
Conference Call Today at 4:30 p.m. ET
May 04, 2017
Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk Prostate Cancer
Once New LCD is Finalized, 80,000 Medicare Patients Total Will Be Eligible for Coverage
May 04, 2017
Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases
Data from American Urological Association 2017 Annual Meeting Establishes Oncotype DX as First Genomic Prostate Cancer Test to Predict Both Near-term Adverse Pathology and Long-term Outcomes
May 02, 2017
Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
REDWOOD CITY, Calif. , May 2, 2017 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 9 at 4:30 p.m. Eastern Time to discuss its first quarter 2017 financial results.  The call and webcast will follow the